| SDS-19CAR / Innovative Cellular Therapeutics |
ChiCTR1800015817: CD19 targeted Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed non - Hodgkin's lymphoma |
|
|
| Recruiting | 1/2 | 10 | | CD19 CART cell | The First Affiliated Hospital of Medical School of Zhejiang University; Peking University Third Hospital, Innovative Cellular Therapeutics Co.,Ltd. | Refractory Aggressive Non-Hodgkin Lymphoma (NHL) | | | | |
ChiCTR1800014952: Clinical Study on the Safety and Efficacy of Commercialized CD19CART Cells in the Treatment of Refractory, Invasive Non-Hodgkin's Lymphoma (NHL) |
|
|
| Recruiting | 1 | 6 | | off-the-shelf CART | He'nan Province Cancer Hospital; Innovative Cellular Therapeutics Co., Ltd., Self-raised | DLBCL | | | | |
ChiCTR1800014953: Clinical Study on the Safety and Efficacy of CD19CART Cell Therapy for Refractory B-Cell Leukemia |
|
|
| Recruiting | 1 | 6 | | off-the-shelf CART | Henan Province Cancer Hospital; Innovative Cellular Therapeutics Co., Ltd., Self-raised | r/r B-ALL | | | | |
ChiCTR1800014956: Clinical Study on the Safety and Efficacy of Commercialized CD19CART Cells in the Treatment of Refractory, Invasive Non-Hodgkin's Lymphoma (NHL) |
|
|
| Recruiting | 1 | 6 | | off-the-shelf CART | The Second Affiliated Hospital of Zhejiang University; Innovative Cellular Therapeutics Co., Ltd., Self-raised | DLBCL | | | | |
ChiCTR1800015836: Clinical Study on the Safety and Efficacy of CD19CART Cell Therapy for Refractory B-Cell Leukemia |
|
|
| Recruiting | 1 | | | CD19CART | Peking University Third Hospital; Peking University Third Hospital, Innovative Cellular Therapeutics Co.,Ltd. | r/r B-ALL | | | | |
ChiCTR1900021295: PD1 CD19 targeted Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed non-Hodgkin's lymphoma |
|
|
| Not yet recruiting | 1 | 5 | | PD1 CART Cells | Shanghai Oriental Hospital; Shanghai Oriental Hospital, Innovative Cellular Therapeutics Co.,Ltd. | Refractory Aggressive Non-Hodgkin Lymphoma (NHL) | | | | |
ChiCTR1800017634: Clinical Study on the Safety and Efficacy of CD19CART Cell Therapy for Refractory B-Cell Leukemia |
|
|
| Not yet recruiting | 1 | 2 | | CD19CART cells | First people's Hospital of Yunnan Province; First people's Hospital of Yunnan Province, Innovative Cellular Therapeutics Co.,Ltd. | r/r B-ALL | | | | |
ChiCTR1800017636: CD19 targeted Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed non - Hodgkin's lymphoma |
|
|
| Not yet recruiting | 1 | 2 | | CD19CART cells | First people's Hospital of Yunnan Province; First people's Hospital of Yunnan Province, Innovative Cellular Therapeutics Co.,Ltd. | Refractory Aggressive Non-Hodgkin Lymphoma (NHL) | | | | |
ChiCTR1800017635: CD19 targeted Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed non - Hodgkin's lymphoma |
|
|
| Recruiting | 1 | 2 | | CD19 CAR T cells | Second Affiliated Hospital of Kunming Medical University; Second Affiliated Hospital of Kunming Medical University, Innovative Cellular Therapeutics Co.,Ltd. | Refractory Aggressive Non-Hodgkin Lymphoma (NHL) | | | | |
ChiCTR1800017611: Clinical Study on the Safety and Efficacy of CD19CART Cell Therapy for Refractory B-Cell Leukemia |
|
|
| Recruiting | N/A | 2 | | CD19CART cell | Second Affiliated Hospital of Kunming Medical University; Second Affiliated Hospital of Kunming Medical University, Innovative Cellular Therapeutics Co.,Ltd. | r/r B-ALL | | | | |
